Tech Company Financing Transactions
Exonics Therapeutics Funding Round
On 11/9/2017, Exonics Therapeutics landed $40 million in Series A investment from The Column Group.
Transaction Overview
Company Name
Announced On
11/9/2017
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series A
Investors
The Column Group (David Goeddel)
Proceeds Purpose
This funding from a leading healthcare venture capital firm further validates the potential for Exonics' novel gene editing technology to help correct many of the mutations that cause Duchenne and other neuromuscular diseases, said John Ripple, chief executive officer of Exonics.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Bdwy. 14th Floor
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Website
Email Address
Overview
At Exonics Therapeutics, our mission is to permanently correct genetic mutations resulting in neuromuscular diseases like Duchenne muscular dystrophy. Duchenne is a devastating muscle disease in children, primarily boys, caused by the absence of dystrophin.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Ripple
Chief Scientific Officer
Eric Olson
Browse more venture capital transactions:
Prev: 11/9/2017: Crux Informatics venture capital transaction
Next: 11/9/2017: Rollick venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to record tech company VC transactions. VC transactions on this site are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs